Table 1.
Baseline characteristics, significant differences (p < 0.05) within cohorts depicted with*.
| DVT | DVT | DVT | DVT | DVT | PAD | PAD | |
|---|---|---|---|---|---|---|---|
| No recurrence | Recurrence | PTS | CV event | No CV event | CV event | No CV event | |
| n = 25 | n = 25 | n = 25 | n = 10 | n = 65 | n = 20 | n = 20 | |
| Mean age (SD) | 69.2 (31.4) | 69.5 (11.8) | 73.4 (12.9) | 76 (7.5)* | 69 (13.1) | 68.7 (8.3) | 68.3 (6) |
| Male gender (%) | 21 (84) | 15 (75) | 9 (36) | 7 (70) | 42 (76.4) | 9 (45) | 15 (75)* |
| Anticoagulants (VKA, DOAC) (%) | 17 (68) | 19 (76) | 11 (44) | 7 (70) | 40 (72.7) | 0 (0) | 0 (0) |
| Antiplatelet medication (%) | 0 (0) | 2 (8) | 2 (8) | 3 (30)* | 1 (1.8) | 20 (100) | 18 (90) |
| Statin (%) | 1 (4) | 4 (16) | 3 (12) | 3 (30)* | 5 (9.1) | 14 (70) | 15 (75) |
VKA, vitamin K antagonist; DOAC, direct oral anticoagulant.